Compare CPOP & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPOP | CTXR |
|---|---|---|
| Founded | 2007 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.8M | 18.9M |
| IPO Year | 2020 | 2010 |
| Metric | CPOP | CTXR |
|---|---|---|
| Price | $0.12 | $0.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 27.3M | 426.4K |
| Earning Date | 11-17-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.48 |
| 52 Week High | $2.60 | $2.24 |
| Indicator | CPOP | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 44.36 | 43.43 |
| Support Level | N/A | $0.48 |
| Resistance Level | $0.51 | $0.74 |
| Average True Range (ATR) | 0.32 | 0.04 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 0.41 | 22.86 |
Pop Culture Group Co Ltd hosts entertainment events, operates hip-hop-related online programs, and provides event planning and execution services and marketing services to corporate clients. It generates revenue from Event Hosting business by providing sponsorship packages to advertisers in exchange for sponsorship fees and by selling tickets for those concerts. The company has various operations services out of which Brand Promotion earns maximum revenue, following by Event Hosting, and Event Planning and Execution.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.